10 results about "Liver toxicity" patented technology

The application discloses a compound Chinese herbal medicine fermentation preparation for preventing and treating hepatotoxicity of Penaeus vannamei and a preparation method thereof. Spore bacillus is used as a fermentation strain to perform aerobic fermentation on four traditional Chinese herbal medicine stem and leaf wastes, i.e. Astragalus stem and leaf, Rhubarb stem and leaf, Codonopsis stem and leaf and Coptis stem and leaf, so as to obtain a compound Chinese herbal medicine fermentation product with higher active substances. The compound Chinese herbal medicine fermentation preparation of the application can be added into the feed of Penaeus vannamei, so as to effectively prevent and treat hepatotoxicity of Penaeus vannamei.

The present invention discloses the use of a short-term embolic agent in reducing drug accumulation in the liver, hepatic clearance and / or liver toxicity. The present invention provides the use of a short-term embolic agent in the manufacture of a medical composition for: (a) temporarily embolizing blood vessels supplying the liver; and (b) reducing the accumulation of a drug subsequently or concurrently administered intravenously in the liver. The strategy aims to minimize the exposure of a drug (such as LNP) to the liver by temporarily blocking the blood supply to the liver via the portal vein and / or arteries. The present invention significantly reduces the non-specific accumulation of a drug in the liver by temporarily blocking the portal vein, arterial and / or their branch blood flow, thereby greatly reducing the opportunity for the drug to enter the liver from a hemodynamic root.

The application relates to the technical field of pharmaceutical preparations, and discloses an agomelatine inhalant as well as a preparation method and application thereof. The agomelatine inhalant provided by the application comprises agomelatine or a pharmaceutically acceptable salt thereof in a form capable of being inhaled or capable of being changed into a form capable of being inhaled after being excited. From the aspect of synergism, the inhalant can avoid first-pass metabolism by changing a drug administration route, significantly improve bioavailability, and realize rapid effect by directly entering blood from the lung; from the aspect of attenuation, the inhalant can greatly reduce a drug usage amount to achieve a same treatment effect as a tablet, significantly reduce occurrence of drug toxic and side reactions, and significantly reduce liver toxicity by avoiding liver metabolism.

The application discloses application of a GPR120 agonist in preventing or treating intestinal-liver immunological injury induced by poultry acetochlor poisoning. According to the intestinal-liver toxicity of chicken acetochlor, the normal expression of G protein-coupled receptor 120 is mainly changed. Subsequently, programmed cell death occurs in the intestinal tract and the liver, and a large amount of inflammatory factor release is caused; the intestinal-liver axis immunological injury is improved by activating the G protein-coupled receptor 120 in vivo and in vitro, so as to rescue the chicken acetochlor poisoning reaction. The application provides a prevention and treatment basis for poultry acetochlor poisoning immunological injury diseases, provides medical data for developing poultry immunological activity drugs or supplements, and also provides more technical means for developing and utilizing environment-friendly, efficient, targeted and slow-release new veterinary drug preparations.

The application discloses a microfluidic device and method for evaluating drug idiosyncratic hepatotoxicity, wherein the microfluidic device comprises a microfluidic chip, the microfluidic chip comprises a lower substrate and an upper substrate, the upper substrate is provided with a first culture channel and a second culture channel, the first culture channel and the second culture channel are communicated through a micro fence, and the first culture channel and the second culture channel are respectively provided with corresponding fluid interfaces; the upper substrate is further provided with a liquid storage pool, the liquid storage pool is communicated with the second culture channel; wherein the first culture channel is used for culturing liver cells, the second culture channel is used for culturing immune cells, and the liquid storage pool is used for storing culture medium; and the micro fence is configured to allow the culture medium and the immune cells to pass through, but not allow the liver cells to pass through. The microfluidic device provided by the application can realize evaluation of drug idiosyncratic hepatotoxicity.

The present invention relates to a formulation in particular an oral formulation for the prophylaxis and treatment of TG2-related disorders like fibrosis in particular diabetic nephropathy and / or diabetic associated non-alcoholic steatohepatitis (NASH) and / or non-alcoholic steatohepatitis, and its use in the prophylaxis and / or treatment of fibrosis in particular nephropathy, NASH, idiopathic pulmonary fibrosis, and cystic fibrosis. Further, the present application relates also to the use of (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate as hepatoprotectant, i.e. as hepatoprotective agent. In addition the present invention relates to a pharmaceutical composition comprising (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate for use as hepatoprotective agent and for use in the protection of the liver against liver toxicity, the improvement of liver function, and / or in the prophylaxis or treatment of a liver disease or liver disorder.

This invention belongs to the field of natural product extraction and biomedicine technology, and discloses a carrageenan polysaccharide ATSP-1 derived from Taxus chinensis and its applications. This polysaccharide, obtained through hot water extraction and purification, has a triple helix conformation, is mainly composed of galactose, has a weight-average molecular weight of 725.95 kDa, and its backbone contains specific glycosidic bonds and differentiated sulfation patterns. ATSP-1 can upregulate the expression of MHC-I / II molecules in colonic tissue through the antigen presentation signaling pathway, thereby activating CD4+. + / CD8 + It induces specific immune responses mediated by T cells; simultaneously activates the p53 apoptosis pathway, induces tumor cell apoptosis, achieves a tumor inhibition rate of 43.14%, and has no significant liver toxicity. It can be used to prepare immune-related anti-tumor products and provides natural active polysaccharide resources.

The present application relates to a kind of testosterone microcrystal, freeze-dried powder injection, suspension and its preparation method.The particle size range of testosterone microcrystal meets: D90≤20 μm.Testosterone microcrystal freeze-dried powder injection includes testosterone microcrystal, suspending agent and freeze-drying protective agent;The mass ratio of the suspending agent and the mass of the testosterone microcrystal meets (0.3-2):1.The particle size range of the testosterone microcrystal meets: D90≤20 μm.Testosterone microcrystal suspension includes water, testosterone microcrystal, suspending agent and freeze-drying protective agent;The concentration of the suspending agent is 0.3%-2%.The preparation of testosterone microcrystal prepared in the present application is short-acting preparation, has the advantages of small liver toxicity, dose accuracy and easy to use.

The application discloses application of a copper-containing compound in preparation of a medicine for preventing and / or treating obesity and related metabolic diseases. The application breaks through the traditional cognition on safety of high-dose copper, and proves that oral administration of the copper-containing compound (such as copper chloride) in a specific dose range (calculated according to copper element, such as 0.07-2.84 mg / kg body weight per day) can effectively inhibit weight growth of animals induced by a high-fat diet, and simultaneously has an effect on liver steatosis and body composition, without risk of liver toxicity. Compared with existing weight loss methods, the application scheme has the advantages of low raw material price, convenient oral use, wide safety window, remarkable comprehensive effect and the like, and provides a clear direction and a solid experimental basis for development of a new, economical and safe medicine or health care food for preventing and treating obesity.

The present application relates to the use of platelet factor 4 in the preparation of a drug for treating or preventing Candida albicans infection, platelet factor 4 acts on macrophage CXCR3 receptor, antagonizes Candida albicans induced macrophage PANoptosis, thereby reducing the damage of Candida albicans to macrophages, maintaining the survival and normal function of macrophages, enhancing the clearance ability of the body to Candida albicans, reducing the inflammatory response caused by infection, reducing pathological damage, and different from the treatment mechanism of traditional antifungal drugs, the present application does not directly act on fungi, which helps to reduce the formation of drug-resistant strains and the toxic side effects such as liver toxicity and kidney toxicity caused by antifungal drugs, and can provide a more optimal new treatment mode for clinical Candida albicans infection.